Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials

Multiple Sclerosis

Volumn 21, Issue 10, 2015, Pages 1322-1331

  Goodman, Andrew D ^a   Bethoux, Francois ^b   Brown, Theodore R ^c   Schapiro, Randall T ^d   Cohen, Ron ^e   Marinucci, Lawrence N ^e   Henney, Herbert R ^e   Blight, Andrew R ^e  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Evergreen Neuroscience Institute   (United States)

^d Schapiro Multiple Sclerosis Advisory Group   (United States)

^e ACORDA THERAPEUTICS INC   (United States)

Author keywords

Clinical trial; dalfampridine; efficacy; long term effects; multiple sclerosis; safety; sustained release; Timed 25 Foot Walk; tolerability; walking speed

Indexed keywords

FAMPRIDINE; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BALANCE DISORDER; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; COMPLEX PARTIAL SEIZURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; CONVULSION; CYSTITIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HUMAN; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE WEAKNESS; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); RHINOPHARYNGITIS; SEIZURE; SPASTICITY; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WALKING DIFFICULTY; WALKING SPEED; AGED; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; EUROPE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WALKING; ASSESSMENT OF HUMANS; DELAYED DRUG RELEASE; DISEASE DURATION; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE PREPARATION; TIMED 25 FOOT WALK TEST; TREATMENT DURATION; TREATMENT RESPONSE;

4-AMINOPYRIDINE; ADULT; AGED; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS; TREATMENT OUTCOME; WALKING;

EID: 84940904085     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514563591     Document Type: Article

References (15)

1. Gold MR, Siegel JE, Russell LB, Weinstein MC, (eds) Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
2. Goldman MD, Marrie RA, Cohen JA,. Evaluation of the Six-Minute Walk in multiple sclerosis subjects and healthy controls. Mult Scler 2008; 14: 383-390.
3. Burschka JM, Keune PM, Menge U,. An exploration of impaired walking dynamics and fatigue in multiple sclerosis. BMC Neurol 2012; 12: 161.
4. Salter AR, Cutter GR, Tyry T,. Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin 2010; 26: 493-500.
5. Coleman CI, Sidovar M, Roberts MS,. Walking speed and health-related quality of life in multiple sclerosis. Int J MS Care 2012; 14: S29.
6. Coleman CI, Sidovar MF, Roberts MS,. Impact of mobility impairment on indirect costs and health-related quality of life in multiple sclerosis. PLoS One 2013; 8: e54756.
7. Pike J, Jones E, Rajagopalan K,. Social and economic burden of walking and mobility problems in multiple sclerosis. BMC Neurol 2012; 12: 94.
8. Dunn J, Blight A., Dalfampridine: A brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Op 2011; 27: 1415-1423.
9. Goodman AD, Brown TR, Krupp L,. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet 2009; 373: 732-738.
10. Goodman AD, Brown TR, Edwards KR,. A Phase 3 trial of extended release oral dalfampridine in mulitple sclerosis. Ann Neurol 2010; 68: 494-502.
11. Goodman AD, Brown TR, Schapiro RT,. A pooled analysis of two Phase 3 clinical trials of dalfampridine in patients with multiple sclerosis. Int J MS Care 2014; 16: 153-160.
12. Koch M, Uyttenboogaart M, Polman S,. Seizures in multiple sclerosis. Epilepsia 2008; 49: 948-953.
13. Kelley BJ, Rodriguez M., Seizures in patients with multiple sclerosis: Epidemiology, pathophysiology and management. CNS Drugs 2009; 23: 805-815.
14. Cadavid D, Tang Y, O'Neill G,. Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis. Rev Neurol 2010; 51: 321-329.
15. Cohen JA, Cutter GR, Fischer JS,. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 2002; 59: 679-687.